Amgen and Zai Lab eye a gastric niche
Adverse events will be closely watched when full data are reported.
The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
J&J gets a smouldering endorsement
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
Another TIGIT bites the dust
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
FDA red and green lights: April 2025
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
